Navigation Links
Prolia® (Denosumab) Phase 2 Extension Study Showed Continued Increase in Bone Mineral Density Over Eight Years of Treatment
Date:9/17/2011

fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.

Prolia is approved in the European Union (EU) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.

Prolia is approved in the U.S., Canada, Australia and in all 27 EU member states as well as in Norway, Iceland and Liechtenstein. Applications in the rest of the world are pending.

Prolia is administered as a single subcutaneous injection of 60 mg once every six months. For further information on Prolia, including prescribing information and medication guide, please visit: www.prolia.com.  

Important U.S. Safety Information

Prolia is contraindicated in patients with hypocalcemia. Pre-existing hypocalcemia must be corrected prior to initiating Prolia. Hypocalcemia may worsen, especially in patients with severe renal impairment. All patients should be adequately supplemented with calcium and vitamin D. Patients receiving Prolia should not receive XGEVA® (denosumab), as both Prolia and XGEVA contain the same active ingredient, denosumab.

In the Phase 3 pivotal study, serious infections leading to hospitalizations were reported more frequently in the Prolia-treated patient group. Serious skin infections, as well as infections of the abdomen, urinary tract and ear, were more frequent in patients treated with Prolia. Patients should be advised to seek prompt medical attention if they develop signs or symptoms of severe infection, including cellulitis. Endocarditis was reported more frequently in the Prolia-treated patient group. Epidermal and dermal adverse events such as dermatitis, rashes and eczema have been reported. Discontinuation of Prolia should be considered if severe symptoms develop.

Prolia resulted
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate
2. Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial
3. XGEVA® (Denosumab) Granted Marketing Authorization in the European Union
4. Amgen Receives CHMP Positive Opinion for XGEVA™ (Denosumab) in the European Union
5. Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer
6. The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma
7. XGEVA™ (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer
8. Amgen Presents New XGEVA™ (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS
9. Prolia™ (denosumab) Receives Best New Drug Honor at Scrip Awards
10. Vantage Health Announces That All of Its Required Tanzanian Registrations, Permits and Licenses Have Been Formally Issued, Simultaneous With Official Notification That Its Application for Phase One Evaluation of Its HIV Screening Test Kits Has Been
11. Soligenix Announces Results of Recent Data Safety Monitoring Board Review for Phase 3 orBec® Study in Acute GI GVHD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... July 1, 2015 Egalet Corporation (Nasdaq: ... pharmaceutical company focused on developing, manufacturing and marketing ... Radie , president and chief executive officer, is ... He will provide an update on Egalet,s marketed ... Nasal Spray, approved product OXAYDO ™ (oxycodone ...
(Date:7/1/2015)... , July 1, 2015 New exchange ... quarter of 2015 compared to the same time a ... Express Scripts (NASDAQ: ESRX ) Exchange Pulse™ report, ... quarter of 2014, the number of new exchange plan ... 18 percent in the first quarter of 2015. However, ...
(Date:7/1/2015)... 1, 2015 The Haselmeier Group ... Mr. Gert Weber has been nominated by ... Chief Executive Officer (CEO) of the Haselmeier ... , 2015. Mr. Weber brings more than 20 years ... has filled various executive management positions, the last being ...
Breaking Medicine Technology:Egalet to Present at Upcoming Conferences This Summer 2Egalet to Present at Upcoming Conferences This Summer 3Express Scripts Provides First Look at 2015 Public Exchange Pharmacy Trends 2Express Scripts Provides First Look at 2015 Public Exchange Pharmacy Trends 3Express Scripts Provides First Look at 2015 Public Exchange Pharmacy Trends 4Express Scripts Provides First Look at 2015 Public Exchange Pharmacy Trends 5Haselmeier Group Announces the Extension and Reorganization of its Executive Board 2
... The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine ... as its July 2010 "Stock to Study" and Gilead ... for investors, informational and educational use. , ... "The committee chose Teva Pharmaceutical Industries because of the tremendous ...
... EAST BRUNSWICK, N.J. , April 30 Savient Pharmaceuticals, Inc. (Nasdaq: ... the first quarter 2010 following the close of the market on Wednesday ... , ... Financial Officer, will host an investment community conference call beginning at 10:00 ...
Cached Medicine Technology:BetterInvesting Magazine Releases July's Stock to Study and Undervalued Stock Choices for Investors' Informational and Educational Use 2BetterInvesting Magazine Releases July's Stock to Study and Undervalued Stock Choices for Investors' Informational and Educational Use 3Savient Pharmaceuticals To Hold First Quarter 2010 Results 2
(Date:7/1/2015)... , ... July 01, 2015 , ... For decades, researchers ... wound, histones, remain constant in the brain, never changing after development in the womb. ... histones are steadily replaced in brain cells throughout life – a process which helps ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... ... organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community ... today announced that they will welcome four new members to their industry leading ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... ... technology and services, today announced that its fifth annual Smile for a Lifetime ... $80,000 for the non-profit organization. In addition to supporting S4L in its mission ...
(Date:7/1/2015)... , ... July 01, 2015 , ... ... a new extraction plant for Linablue®, Spirulina-derived natural blue food coloring. Construction of ... the DIC Group’s U.S. Spirulina* production base, began in May 2014. After commissioning, ...
(Date:7/1/2015)... ... July 01, 2015 , ... The Collaborative for Children and Families (CCF) ... The grant will allow CCF to improve quality of care and save costs for ... to respond to many changes in New York’s Medicaid system. Experts agree that children ...
Breaking Medicine News(10 mins):Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 2Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 3Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 4Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 2Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 3Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 4Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 5Health News:The Forum Fundraiser Raises $80,000 for the Smile for a Lifetime Foundation 2Health News:The Forum Fundraiser Raises $80,000 for the Smile for a Lifetime Foundation 3Health News:DIC Strengthens Its Position as the Global Leader for Natural Blue Food Coloring 2Health News:DIC Strengthens Its Position as the Global Leader for Natural Blue Food Coloring 3Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 2Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 3
... Sellamuthu, has ordered distribution of AIDS/HIV awareness calendar to ... tea stalls, hair cutting saloons and Indian Made Foreign ... large number of public gather. The idea of AIDS ... Control Society (TANSACS), according to the officials the calendar ...
... smokers or those who have been smoking in the past have ... tomography (CT scan) to detect // lung cancer if any, ... effective treatment and thereby improve the prognosis. ,The ... family history of the dreadful disease. For those of you ...
... to effective weight loss apart from diet and exercise. ... several myths abound // . Let’s throw some light ... and dispel famous myths to reveal underlying truths!, ,Body ... happens when calorie intake exceeds calories expended. The extra ...
... doctors of Indian origin live in a state of penury in ... of them even have decent // lodgings. This is the ... to serve in the country in 2001, which had resulted in ... ,Most of them are faced with discrimination and unemployment ...
... made news recently due to its wide spreading nature across the ... its // spread across the country. It ... reduced and area, which has been infected with the avian flu, ... that previously there were21 provinces affected with bird flu but now ...
... now proven by research. Apparently genuine laughter is the ... Review of Biology//. ,The study, which explains how ... that there are two types of laughter – genuine and ... second, is strategic and, at times, downright cruel, also nicknamed ...
Cached Medicine News:Health News:CT Scan A Must For Smokers With Family History Of Lung Cancer 2Health News:The weight loss reality check – Do Fad diets and short-cut methods actually work 2Health News:Genuine Laughter Is The Best Medicine! 2
... isolation chamber provides a safe, clean ... pharmaceuticals, in accord with USP-797 requirements. ... (ISO 5) cleanliness conditions in the ... rod and tilt-up front panel for ...
... testing at various temperatures, this chamber ... a clean heating unit to maintain ... 140F. Transparent panels allow full visibility, ... access to the work area. Includes ...
... Ventilates and removes chemical fumes, ... exhaust. Bonded charcoal filters remove ... ensure safe exhaust flow speed ... access opening. Includes air speed ...
... exhaust hood ventilates and purifies hazardous ... of exhaust. Bonded charcoal filters remove ... vertical clearance (with access shield open) ... tray; options include final HEPA filter, ...
Medicine Products: